Aminocamptothecin in Treating Patients With Refractory or Recurrent Hodgkin's Disease or Non-Hodgkin's Lymphoma

Completed · Phase 2

Conditions studied: Lymphoma

In brief

Phase II trial to study the effectiveness of aminocamptothecin in treating patients who have refractory or recurrent Hodgkin's disease or non-Hodgkin's lymphoma. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

Key facts

Study ID

NCT00002745

Run by

National Cancer Institute (NCI)

People needed

37

Starts

1996-04-01

Expected to finish

2008-01-01

Last updated by the study team

2013-02-11

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Walter Reed Army Medical Center — Washington D.C., District of Columbia, United States
• University of Minnesota Cancer Center — Minneapolis, Minnesota, United States
• Washington University Barnard Cancer Center — St Louis, Missouri, United States
• Cooper Cancer Institute — Camden, New Jersey, United States
• St. Joseph's Hospital and Medical Center — Paterson, New Jersey, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.